Do analysts prefer BIVI or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score BioVie 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer PLUR or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Pluri 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts prefer LTRN or BRTX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Lantern Pharma 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Biorestorative Therapies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate PHIO or BRTX?

Phio Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,374.30%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Biorestorative Therapies. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Phio Pharmaceuticals 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Biorestorative Therapies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50

Do analysts rate BRTX or BLRX?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Biorestorative Therapies 1 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.50 BioLineRx 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Biorestorative Therapies (BRTX) Competitors

$1.50 -0.09 (-5.66%)

Closing price 10/14/2026 03:58 PM Eastern

Extended Trading

$1.46 -0.03 (-2.33%)

As of 07:15 AM Eastern

Compare

BRTX vs. BIVI, PLUR, LTRN, PHIO, and BLRX

Should you buy Biorestorative Therapies stock or one of its competitors? Biorestorative Therapies's main competitors and comparable companies include BioVie (BIVI), Pluri (PLUR), Lantern Pharma (LTRN), Phio Pharmaceuticals (PHIO), and BioLineRx (BLRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Biorestorative Therapies compare to BioVie?

BioVie (NASDAQ:BIVI) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better investment? We will contrast the two businesses based on the strength of their valuation, risk, institutional ownership, dividends, earnings, analyst recommendations, media sentiment and profitability.

4.6% of BioVie shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 16.7% of BioVie shares are held by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, BioVie had 3 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for BioVie and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.79 beat BioVie's score of 0.45 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
BioVie	Neutral
Biorestorative Therapies	Very Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioVie	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Biorestorative Therapies has higher revenue and earnings than BioVie. BioVie is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioVie	N/A	N/A	-$22.07M	-$3.15	N/A
Biorestorative Therapies	$360K	5.75	-$14.24M	-$21.40	N/A

BioVie has a beta of 0.73, suggesting that its share price is 27% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.94, suggesting that its share price is 6% less volatile than the broader market.

BioVie has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. BioVie's return on equity of -126.02% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioVie	N/A	-126.02%	-108.88%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Summary

BioVie and Biorestorative Therapies tied by winning 6 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Pluri?

Pluri (NASDAQ:PLUR) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, institutional ownership, analyst recommendations, risk, profitability, valuation, earnings and dividends.

16.6% of Pluri shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 43.2% of Pluri shares are owned by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Pluri	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Pluri has a net margin of -2,344.59% compared to Biorestorative Therapies' net margin of -3,088.27%. Pluri's return on equity of 0.00% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Pluri	-2,344.59%	N/A	-82.71%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Biorestorative Therapies has lower revenue, but higher earnings than Pluri. Pluri is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Pluri	$1.02M	11.50	-$23.82M	-$2.45	N/A
Biorestorative Therapies	$360K	5.75	-$14.24M	-$21.40	N/A

In the previous week, Pluri had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for Pluri and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.79 beat Pluri's score of 0.83 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Pluri	Positive
Biorestorative Therapies	Very Positive

Pluri has a beta of 0.69, meaning that its stock price is 31% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Summary

Pluri beats Biorestorative Therapies on 8 of the 13 factors compared between the two stocks.

How does Biorestorative Therapies compare to Lantern Pharma?

Lantern Pharma (NASDAQ:LTRN) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, institutional ownership, valuation, earnings, analyst recommendations, media sentiment, dividends and profitability.

Biorestorative Therapies has higher revenue and earnings than Lantern Pharma. Lantern Pharma is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lantern Pharma	N/A	N/A	-$17.12M	-$1.62	N/A
Biorestorative Therapies	$360K	5.75	-$14.24M	-$21.40	N/A

Lantern Pharma has a beta of 2.33, meaning that its stock price is 133% more volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.94, meaning that its stock price is 6% less volatile than the broader market.

Lantern Pharma has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Lantern Pharma's return on equity of -368.02% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lantern Pharma	N/A	-368.02%	-148.62%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lantern Pharma	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Biorestorative Therapies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

In the previous week, Lantern Pharma had 2 more articles in the media than Biorestorative Therapies. MarketBeat recorded 3 mentions for Lantern Pharma and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.79 beat Lantern Pharma's score of 0.93 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Lantern Pharma	Positive
Biorestorative Therapies	Very Positive

28.6% of Lantern Pharma shares are held by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are held by institutional investors. 8.5% of Lantern Pharma shares are held by insiders. Comparatively, 13.6% of Biorestorative Therapies shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Summary

Lantern Pharma and Biorestorative Therapies tied by winning 6 of the 12 factors compared between the two stocks.

How does Biorestorative Therapies compare to Phio Pharmaceuticals?

Phio Pharmaceuticals (NASDAQ:PHIO) and Biorestorative Therapies (NASDAQ:BRTX) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two businesses based on the strength of their media sentiment, institutional ownership, risk, dividends, analyst recommendations, profitability, earnings and valuation.

Phio Pharmaceuticals has a beta of 0.84, meaning that its share price is 16% less volatile than the broader market. Comparatively, Biorestorative Therapies has a beta of 0.94, meaning that its share price is 6% less volatile than the broader market.

Phio Pharmaceuticals presently has a consensus target price of $14.00, indicating a potential upside of 1,374.30%. Given Phio Pharmaceuticals' stronger consensus rating and higher probable upside, analysts plainly believe Phio Pharmaceuticals is more favorable than Biorestorative Therapies.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Phio Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Biorestorative Therapies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50

Phio Pharmaceuticals has higher earnings, but lower revenue than Biorestorative Therapies. Phio Pharmaceuticals is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Phio Pharmaceuticals	N/A	N/A	-$8.70M	-$1.29	N/A
Biorestorative Therapies	$360K	5.75	-$14.24M	-$21.40	N/A

Phio Pharmaceuticals has a net margin of 0.00% compared to Biorestorative Therapies' net margin of -3,088.27%. Phio Pharmaceuticals' return on equity of -87.41% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Phio Pharmaceuticals	N/A	-87.41%	-79.76%
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%

57.3% of Phio Pharmaceuticals shares are owned by institutional investors. Comparatively, 69.4% of Biorestorative Therapies shares are owned by institutional investors. 3.5% of Phio Pharmaceuticals shares are owned by company insiders. Comparatively, 13.6% of Biorestorative Therapies shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

In the previous week, Phio Pharmaceuticals had 3 more articles in the media than Biorestorative Therapies. MarketBeat recorded 4 mentions for Phio Pharmaceuticals and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.79 beat Phio Pharmaceuticals' score of 1.00 indicating that Biorestorative Therapies is being referred to more favorably in the news media.

Company	Overall Sentiment
Phio Pharmaceuticals	Positive
Biorestorative Therapies	Very Positive

Summary

Phio Pharmaceuticals beats Biorestorative Therapies on 9 of the 14 factors compared between the two stocks.

How does Biorestorative Therapies compare to BioLineRx?

Biorestorative Therapies (NASDAQ:BRTX) and BioLineRx (NASDAQ:BLRX) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, analyst recommendations, profitability, risk, valuation, earnings, institutional ownership and dividends.

69.4% of Biorestorative Therapies shares are owned by institutional investors. Comparatively, 1.6% of BioLineRx shares are owned by institutional investors. 13.6% of Biorestorative Therapies shares are owned by company insiders. Comparatively, 1.1% of BioLineRx shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Biorestorative Therapies has a beta of 0.94, indicating that its share price is 6% less volatile than the broader market. Comparatively, BioLineRx has a beta of 1.61, indicating that its share price is 61% more volatile than the broader market.

BioLineRx has higher revenue and earnings than Biorestorative Therapies. BioLineRx is trading at a lower price-to-earnings ratio than Biorestorative Therapies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Biorestorative Therapies	$360K	5.75	-$14.24M	-$21.40	N/A
BioLineRx	$1.18M	8.78	-$1.17M	-$1.69	N/A

BioLineRx has a net margin of -502.08% compared to Biorestorative Therapies' net margin of -3,088.27%. BioLineRx's return on equity of -34.80% beat Biorestorative Therapies' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Biorestorative Therapies	-3,088.27%	-508.42%	-230.94%
BioLineRx	-502.08%	-34.80%	-18.27%

In the previous week, BioLineRx had 1 more articles in the media than Biorestorative Therapies. MarketBeat recorded 2 mentions for BioLineRx and 1 mentions for Biorestorative Therapies. Biorestorative Therapies' average media sentiment score of 1.79 beat BioLineRx's score of 0.91 indicating that Biorestorative Therapies is being referred to more favorably in the media.

Company	Overall Sentiment
Biorestorative Therapies	Very Positive
BioLineRx	Positive

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biorestorative Therapies	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.50
BioLineRx	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

BioLineRx beats Biorestorative Therapies on 9 of the 13 factors compared between the two stocks.

Get Biorestorative Therapies News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BRTX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

BRTX vs. The Competition

Export

Metric	Biorestorative Therapies	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$2.20M	$3.85B	$7.19B	$13.18B
Dividend Yield	N/A	3.65%	2.52%	19.60%
P/E Ratio	N/A	11.09	221.68	20.80
Price / Sales	5.75	1,089.48	546.08	66.79
Price / Cash	N/A	119.79	76.68	52.75
Price / Book	1.95	16.26	10.41	5.92
Net Income	-$14.24M	-$22.69M	$3.50B	$380.90M
7 Day Performance	-20.63%	-5.80%	-3.49%	-3.90%
1 Month Performance	-43.18%	-12.85%	-7.76%	-6.42%
1 Year Performance	-95.31%	3.03%	0.83%	-6.02%

Biorestorative Therapies Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
BRTX Biorestorative Therapies	1.1854 of 5 stars	$1.50 -5.7%	N/A	-95.3%	$2.20M	$360K	N/A	14	Positive News Gap Down
BIVI BioVie	1.431 of 5 stars	$1.40 -2.8%	N/A	-42.0%	$12.50M	N/A	N/A	13	News Coverage
PLUR Pluri	0.7486 of 5 stars	$1.04 +5.1%	N/A	-79.3%	$12.22M	$1.02M	N/A	113	High Trading Volume
LTRN Lantern Pharma	0.9315 of 5 stars	$0.91 -4.6%	N/A	-84.6%	$12.19M	N/A	N/A	16
PHIO Phio Pharmaceuticals	4.5108 of 5 stars	$1.00 +0.5%	$14.00 +1,300.7%	-57.2%	$11.55M	N/A	N/A	6	Short Interest Decrease Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:BRTX) was last updated on 10/15/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Biorestorative Therapies (BRTX) Competitors

BRTX vs. BIVI, PLUR, LTRN, PHIO, and BLRX

How does Biorestorative Therapies compare to BioVie?

Summary

How does Biorestorative Therapies compare to Pluri?

Summary

How does Biorestorative Therapies compare to Lantern Pharma?

Summary

How does Biorestorative Therapies compare to Phio Pharmaceuticals?

Summary

How does Biorestorative Therapies compare to BioLineRx?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Biorestorative Therapies (BRTX) Competitors

BRTX vs. BIVI, PLUR, LTRN, PHIO, and BLRX

How does Biorestorative Therapies compare to BioVie?

Do institutionals & insiders hold more shares of BIVI or BRTX?

Does the media favor BIVI or BRTX?

Do analysts prefer BIVI or BRTX?

Which has higher earnings & valuation, BIVI or BRTX?

Which has more volatility and risk, BIVI or BRTX?

Is BIVI or BRTX more profitable?

Summary

How does Biorestorative Therapies compare to Pluri?

Do insiders and institutionals believe in PLUR or BRTX?

Do analysts prefer PLUR or BRTX?

Is PLUR or BRTX more profitable?

Which has stronger valuation and earnings, PLUR or BRTX?

Does the media favor PLUR or BRTX?

Which has more volatility & risk, PLUR or BRTX?

Summary

How does Biorestorative Therapies compare to Lantern Pharma?

Which has stronger earnings and valuation, LTRN or BRTX?

Which has more risk and volatility, LTRN or BRTX?

Is LTRN or BRTX more profitable?

Do analysts prefer LTRN or BRTX?

Does the media favor LTRN or BRTX?

Do insiders and institutionals hold more shares of LTRN or BRTX?

Summary

How does Biorestorative Therapies compare to Phio Pharmaceuticals?

Which has more risk & volatility, PHIO or BRTX?

Do analysts rate PHIO or BRTX?

Which has higher earnings and valuation, PHIO or BRTX?

Is PHIO or BRTX more profitable?

Do institutionals and insiders believe in PHIO or BRTX?

Does the media favor PHIO or BRTX?

Summary

How does Biorestorative Therapies compare to BioLineRx?

Do insiders and institutionals have more ownership in BRTX or BLRX?

Which has more volatility & risk, BRTX or BLRX?

Which has better valuation and earnings, BRTX or BLRX?

Is BRTX or BLRX more profitable?

Does the media prefer BRTX or BLRX?

Do analysts rate BRTX or BLRX?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

BRTX vs. The Competition

Biorestorative Therapies Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools